Murat O Arcasoy

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain
    Murat O Arcasoy
    Department of Medicine, Divisions of Hematology and Medical Oncology, Duke University Medical Center, DUMC Box 3912, Durham, NC 27710
    Biochim Biophys Acta 1740:17-28. 2005
  2. ncbi Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 2:e549. 2007
  3. ncbi Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Mol Cancer Ther 5:356-61. 2006
  4. ncbi Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
    Jacob P Laubach
    Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Exp Hematol 37:1411-22. 2009
  5. ncbi Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia
    Murat O Arcasoy
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:20-7. 2005
  6. ncbi Erythropoietin and erythropoietin receptor expression in human prostate cancer
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC27710, USA
    Mod Pathol 18:421-30. 2005
  7. ncbi Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway
    Ping Fu
    Department of Medicine, Hematology Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Biochem Biophys Res Commun 379:696-701. 2009
  8. ncbi Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Br J Haematol 130:121-9. 2005
  9. ncbi The non-haematopoietic biological effects of erythropoietin
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Br J Haematol 141:14-31. 2008
  10. ncbi Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:4685-90. 2008

Collaborators

Detail Information

Publications24

  1. ncbi Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain
    Murat O Arcasoy
    Department of Medicine, Divisions of Hematology and Medical Oncology, Duke University Medical Center, DUMC Box 3912, Durham, NC 27710
    Biochim Biophys Acta 1740:17-28. 2005
    ..These findings suggest that both tyrosine residues Y285 and Y344 in the cytoplasmic domain of EPOR-ME may contribute to increased Epo sensitivity that is characteristic of PFCP phenotype...
  2. ncbi Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 2:e549. 2007
    ..We investigated the role of the hematopoietic cytokine erythropoietin as an angiogenic factor that modulates tumor progression...
  3. ncbi Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Mol Cancer Ther 5:356-61. 2006
    ....
  4. ncbi Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
    Jacob P Laubach
    Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Exp Hematol 37:1411-22. 2009
    ..We investigated the pathogenesis of PV to characterize abnormal proliferation and apoptosis responses and aberrant oncogenic pathway activation in primary PV erythroid precursors...
  5. ncbi Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia
    Murat O Arcasoy
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:20-7. 2005
    ....
  6. ncbi Erythropoietin and erythropoietin receptor expression in human prostate cancer
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC27710, USA
    Mod Pathol 18:421-30. 2005
    ..The coexpression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer cells suggests the potential for growth regulation by erythropoietin-erythropoietin receptor in an autocrine or paracrine manner...
  7. ncbi Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway
    Ping Fu
    Department of Medicine, Hematology Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Biochem Biophys Res Commun 379:696-701. 2009
    ..These findings suggest that EpoR over-expression and activation in breast cancer cells has the potential to contribute to tumor progression by promoting the proliferation and invasiveness of the neoplastic cells...
  8. ncbi Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Br J Haematol 130:121-9. 2005
    ..In conclusion, Epo- and Scf-mediated co-operative, synergistic expansion of primary erythroid precursors requires selective activation of multiple signalling pathways, including the Jak-Stat, PI3K and MAPK pathways...
  9. ncbi The non-haematopoietic biological effects of erythropoietin
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Br J Haematol 141:14-31. 2008
    ..This review focuses on the scientific evidence documenting the biological effects of Epo in non-haematopoietic tissues and discusses potential future applications of Epo and its derivatives in the clinic...
  10. ncbi Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:4685-90. 2008
    ....
  11. ncbi Expression of erythropoietin receptor splice variants in human cancer
    Murat O Arcasoy
    Department of Medicine, Division of Hematology Medical Oncology, Duke University School of Medicine, DUMC Box 3912, Durham, NC 27710, USA
    Biochem Biophys Res Commun 307:999-1007. 2003
    ..These findings indicate the expression of multiple EPOR isoforms in human cancer cells that may modulate the cellular effects of recombinant human EPO or EPO-EPOR antagonists...
  12. ncbi Aplastic anaemia as an autoimmune complication of thymoma
    Murat O Arcasoy
    Duke University Medical Center, Hematology-Medical Oncology Durham, NC, USA
    Br J Haematol 137:272. 2007
  13. ncbi Erythropoietin biology in cancer
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Clin Cancer Res 12:332-9. 2006
    ..This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells...
  14. ncbi Erythropoietin for oncology supportive care
    Matthew McKinney
    Department of Medicine, Duke University School of Medicine, Durham, NC, USA
    Exp Cell Res 317:1246-54. 2011
    ....
  15. ncbi Functional significance of erythropoietin receptor expression in breast cancer
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Lab Invest 82:911-8. 2002
    ..These studies demonstrate the expression of functional receptors for EPO in breast cancer cells...
  16. ncbi A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis
    Murat O Arcasoy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 99:3066-9. 2002
    ..Expression of mutant EpoR in interleukin 3-dependent hematopoietic cells was associated with Epo hyperresponsiveness compared to cells expressing wild-type EpoR...
  17. ncbi Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis
    Ping Fu
    Department of Medicine, Duke University School of Medicine, DUMC Box 3912, Durham, NC 27710, USA
    Biochem Biophys Res Commun 354:372-8. 2007
    ..Erythropoietin may serve as a novel cardioprotective agent against anthracycline-induced cardiotoxicity...
  18. ncbi Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells
    Lei Wang
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520 8021, USA
    Exp Hematol 33:308-17. 2005
    ..We now studied if EPOR signaling could also mediate secondary granule protein gene expression and investigated the signal transduction requirements for induction of secondary granule gene expression in 32D cells...
  19. ncbi A novel role for erythropoietin during fibrin-induced wound-healing response
    Zishan A Haroon
    Synergenics, San Francisco, California, USA
    Am J Pathol 163:993-1000. 2003
    ..These data demonstrate a novel function for EPO by providing in vivo evidence for a physiological role during fibrin-induced wound healing...
  20. ncbi Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis
    Suzanne Burns
    South Texas Veterans Health Care System, and Department of Medicine, Division of Hematology, University of Texas Health Science Center, San Antonio, TX, USA
    Blood 99:4400-5. 2002
    ..Yeast-expressed Epo (R103A) is a specific inhibitor of primary erythropoiesis suitable for testing in animal models...
  21. ncbi Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury
    Gary L Wright
    Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
    FASEB J 18:1031-3. 2004
    ..These experiments revealed that the rapid cardioprotective effect of EPO during ischemia-reperfusion injury was associated with preservation of ATP levels in the ischemic myocardium...
  22. ncbi T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil
    Murat O Arcasoy
    Am J Hematol 78:161-3. 2005
  23. ncbi Erythropoiesis-stimulating agents in cancer
    Murat O Arcasoy
    J Clin Oncol 26:3097-8; author reply 3098-100. 2008
  24. ncbi Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling
    Paul R Hanlon
    Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
    FASEB J 19:1323-5. 2005
    ..Postischemia cardioprotection by EPO required the PI3K pathway but was not affected by inhibition of PKC at the time of EPO treatment...